CN107602550B - A kind of inhibitors of fatty amide hydrolase and preparation method thereof - Google Patents
A kind of inhibitors of fatty amide hydrolase and preparation method thereof Download PDFInfo
- Publication number
- CN107602550B CN107602550B CN201711010260.7A CN201711010260A CN107602550B CN 107602550 B CN107602550 B CN 107602550B CN 201711010260 A CN201711010260 A CN 201711010260A CN 107602550 B CN107602550 B CN 107602550B
- Authority
- CN
- China
- Prior art keywords
- amide hydrolase
- fatty amide
- inhibitors
- mmol
- faah
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Abstract
The invention discloses a kind of inhibitors of fatty amide hydrolase and preparation method thereof, structural formula isWherein, X is selected from C or N；R1Selected from H or C；R2Selected from H, C or F；R3Selected from H, C, F or CH2CH3.Compound by test has inhibitory activity well, IC for people and rat fat hydroamidase50Value is within the scope of 2nM to 127nM.Illustrate the follow-up research and development that the compound of the present invention can be as inhibitors of fatty amide hydrolase for the preparation of related drugs.
Description
Technical field
The present invention relates to a kind of inhibitors of fatty amide hydrolase and preparation method thereof, belong to pharmaceutical chemistry, Pharmaceutical Analysis,
The combination in the fields such as pharmaceutical preparation and pharmaceutical activity test.
Background technology
Fatty amide hydrolase（Fatty acid amide hydrolase, FAAH）It is a kind of inner membrance amide FAAH signals
Family protein enzyme, it is many biologically active fatty acid amides in organism（Fatty acid amide）Messenger molecule
Major catalytic hydrolyzes metabolic enzyme.The fatty amide hydrolase being originally found is found in liver by Schmid and his colleagues
N- acyl ethanol amines amidohydrolase.This hydrolase can be by N- acyl ethanol amines（NAE）Hydrolysis generate aliphatic acid and
Ethanol amine.1996, Cravatt etc. came out this enzyme clone, is named as fatty amide hydrolase（FAAH）.In human body
Fatty amide hydrolase enzyme contains 597 amino acid, molecular weight 63KDa.Fatty amide hydrolase is mainly distributed on microsome
And on the film of mitochondria.FAAH is appeared in Various Tissues, including head, intestines, liver, testis, uterus, kidney, eyes, spleen and lung etc..
In the brain, FAAH is also different in not same district expression degree, most strong in globus pallidus region and hippocampus activity, and in brains
Activity is worst；In immune system, FAAH activity is by lymphocyte and Expression of Macrophages.FAAH is as endocannabinoids system
The forming member of system plays an important role to the termination of cannboid signal, be the nervous system disease, inflammation, metabolic disease and
The potential target spot for the treatment of cardiovascular disease.
The catalytic center of FAAH is the catalytic triads that Ser241, Ser217 and Lysl42 are constituted, and contains multiple channels
And chamber, including film access channel（Membrane access channel, MAC）, by active site and electrodes method film surface phase
Even；Cytoplasm accesses channel, and hydroaropic substance is allowed to exit activated centre（cytosolic access channel）；In conjunction with fat
The hydrophobic region of fat acid chain is known as fatty acid chain combined area（Acyl chain-binding pocket, ABP）, eutectic is adjusted
The fatty acid chain of body inhibitor.
Although not there is the listing of FAAH inhibitor also at present, has multiple drugs and surveyed in clinical and preclinical bioactivity
The examination stage.According to Thomson Reuters Cortellis statistics of database, there are multiple drugs to be in conceptual phase at present.
Invention content
One of the objects of the present invention is to provide a kind of inhibitors of fatty amide hydrolase, structural formula is
Wherein, X is selected from C or N；R1Selected from H or C；R2Selected from H, C or F；R3Selected from H, C, F or CH2CH3。
Further, salt or its solvated compounds.
Another object of the present invention is to provide a kind of synthetic routes of inhibitors of fatty amide hydrolase：
。
Another object of the present invention is to provide a kind of inhibitors of fatty amide hydrolase for treating, preventing or assisting to control
Treat the application in adjusting fatty amide hydrolase relevant disease in mammal and people, the disease such as pain, including it is acute
And it is chronic, the pain as caused by postoperative pain, chronic pain, pain caused by cancer, cancer chemotherapy, neuralgia, nociception pain, inflammatory
Bitterly, backache, the pain caused by the disease such as following various sources：Diabetic neuropathy including human immunodeficiency virus
Thermophilic nervous system type viral disease, pain such as post herpetic neuralgia caused by herpes zoster；Polyneuropathy, neurotoxicity, machinery
Neurotrosis, complication of wrist, amynologic mechanism such as multiple sclerosis.
Further, application of the inhibitors of fatty amide hydrolase in the drug for the treatment of pain.
Another object of the present invention is to a kind of compositions, including fatty amide hydrolase described in claim 1 to inhibit
Agent and pharmaceutically acceptable auxiliary material.
Further, the inhibitors of fatty amide hydrolase described in the composition is as sole active agent.
Obviously, the above according to the present invention is not departing from this hair according to the ordinary technical knowledge and means of this field
Under the premise of bright above-mentioned basic fundamental thought, the modification, replacement or change of other diversified forms can also be made.
Specific implementation mode
Intermediate one：The synthesis of the bromo- 1H- pyrroles -2- formyl chlorides of 4-
The bromo- 1H- pyrroles -2- formamides of compound 4- (10 mmol) are dissolved in 30 milliliters of dichloromethane, 5 are added thereto
Milliliter DMF, is then added dropwise 3 grams of thionyl chlorides, is heated to flowing back, and stirs 5 hours, and decompression steams solvent, and 20 millis are added thereto
Toluene is risen, decompression steams toluene and simultaneously takes away remaining thionyl chloride, and products obtained therefrom is directly used in react in next step.1H-NMR
(400 MHz, CDCl3) δ: 7.17-7.22(m, 2H), 8.97(s, 1H)。
Intermediate two：The synthesis of the bromo- N- of 4- (3- methyl-1s, 2,4- thiadiazolyl groups -5) -1H- pyrroles's -2- formamides
The bromo- 1H- pyrroles -2- acyl chlorides of the crude product 4- of previous step is dissolved in 40 milliliters of dichloromethane solutions, is added thereto
10 milliliters of triethylamines, control temperature are less than 10 DEG C, 3- methyl-1s, 2,4- thiadiazoles -5- amine (12 mmol) are added dropwise into system
Dichloromethane solution, restore room temperature after being added dropwise, stirring at normal temperature 10 hours, then the sodium carbonate with 50 milliliter 5% is water-soluble
Liquid washing reaction system, organic phase anhydrous Na2SO4Dry, after solvent evaporated, obtained solid flash column chromatography separation obtains
2.45 g light yellow solids, two step gross production rates 85%.1H-NMR (400 MHz, CDCl3) δ: 2.18(s, 3H), 6.78(d,
1H), 7.16(d, 1H), 8.83(s, 1H)。
Embodiment 1：The synthesis of N- (3- methyl-1s, 2,4- thiadiazolyl groups -5) -4- phenoxy group -1H- pyrrole radicals -2- formamides
The bromo- N- of 4- (3- methyl-1s, 2,4- thiadiazolyl groups -5) -1H- pyrroles -2- formamides (10 mmol) are dissolved in 30 ml
In toluene, copper sulfide (1 mmol) and cesium carbonate (12 mmol) are added thereto, stirs half an hour, phenol (12 is added thereto
Mmol), reacted 10 hours after system is heated to 100 DEG C.Then it is cooled to room temperature, is filtered, solvent evaporated, flash column chromatography point
From it is solid that 2.3 g off-white colors N- (3- methyl-1s, 2,4- thiadiazolyl groups -5) -4- phenoxy group -1H- pyrrole radicals -2- formamides can be obtained
Body, yield 77%.1H-NMR (400 MHz, CDCl3) δ: 2.18(s, 3H), 6.23(d, 1H), 6.45(d,1H),
6.91-7.02(m, 3H), 7.29(m, 2H), 8.64(s, 1H).13C-NMR (75 MHz, CDCl3) δ:17.71,
108.26, 119.9, 120.66, 121.66, 124.89, 129.81, 143.43, 153.96, 162.46,
167.63, 173.89.LC-MS(ESI, pos, ion) m/z: 301[M+1]。
Embodiment 2：N- (3- methyl-1s, 2,4- thiadiazolyl groups -5) -4- (2- pyridines oxygroup) -1H- pyrrole radicals -2- formamides
Synthesis
The bromo- N- of 4- (3- methyl-1s, 2,4- thiadiazolyl groups -5) -1H- pyrroles -2- formamides (10 mmol) are dissolved in 30 ml
In toluene, copper sulfide (1 mmol) and cesium carbonate (12 mmol) are added thereto, stirs half an hour, 2- hydroxyls are added thereto
Pyridine (12 mmol), system are reacted 10 hours after being heated to 100 DEG C.Then it is cooled to room temperature, is filtered, solvent evaporated, quick column
Chromatographic isolation can obtain the faint yellow N- of 2.4 g (3- methyl-1s, 2,4- thiadiazolyl groups -5) -4- (2- pyridines oxygroup) -1H- pyrrole radicals -
2- formamide solids, yield 80%.1H-NMR (400 MHz, CDCl3) δ: 2.15(s, 3H), 6.00(d, 1H),
6.36-6.38(m, 2H), 6.54(dd, 1H), 7.21(dd, 1H), 7.58(dt, 1H), 8.59(s, 1H).13C-
NMR (75 MHz, CDCl3) δ: 17.71, 108.26, 116.02, 118.61, 120.82, 121.66, 137.45,
143.09, 148.62, 162.36, 162.46, 167.63, 173.89.LC-MS(ESI, pos, ion) m/z: 302
[M+1]。
Embodiment 3：N- (3- methyl-1s, 2,4- thiadiazolyl groups -5) -4- (3- fluorophenoxies) -1H- pyrrole radicals -2- formamides
Synthesis
The bromo- N- of 4- (3- methyl-1s, 2,4- thiadiazolyl groups -5) -1H- pyrroles -2- formamides (10 mmol) are dissolved in 30 ml
In toluene, copper sulfide (1 mmol) and cesium carbonate (12 mmol) are added thereto, stirs half an hour, 3- fluorobenzene is added thereto
Phenol (12 mmol), system are reacted 10 hours after being heated to 100 DEG C.Then it is cooled to room temperature, is filtered, solvent evaporated, quick column color
Spectrum separation, can obtain the faint yellow N- of 2.6 g (3- methyl-1s, 2,4- thiadiazolyl groups -5) -4- (3- fluorophenoxies) -1H- pyrrole radicals -2-
Formamide solid, yield 84%.1H-NMR (400 MHz, CDCl3) δ: 2.19(s, 3H), 6.07(d, 1H), 6.44
(d, 1H), 6.68(m, 1H), 7.27(m, 1H), 7.46(m, 1H), 7.60(m, 1H), 8.85(s, 1H).13C-
NMR (75 MHz, CDCl3) δ: 17.71, 108.26, 108.49, 111.04, 116.13, 120.66, 121.66,
131.17, 143.43, 155.32, 162.46, 163.83, 167.63, 173.89.LC-MS(ESI, pos, ion)
m/z:319[M+1]。
Embodiment 4：N- (3- methyl-1s, 2,4- thiadiazolyl groups -5) -4- (to ethyl phenoxy group) -1H- pyrrole radicals -2- formyls
The synthesis of amine
The bromo- N- of 4- (3- methyl-1s, 2,4- thiadiazolyl groups -5) -1H- pyrroles -2- formamides (10 mmol) are dissolved in 30 ml
In toluene, copper sulfide (1 mmol) and cesium carbonate (12 mmol) are added thereto, stirs half an hour, is added thereto to ethyl
Phenol (12 mmol), system are reacted 10 hours after being heated to 100 DEG C.Then it is cooled to room temperature, is filtered, solvent evaporated, quick column
Chromatographic isolation can obtain 2.8 g N- (3- methyl-1s, 2,4- thiadiazolyl groups -5) -4- (to ethyl phenoxy group) -1H- pyrrole radicals -2-
Formamide solid, yield 85%.1H-NMR (400 MHz, CDCl3) δ: 1.18(t, 3H), 2.18(s, 3H), 2.72
(q. 2H). 6.07(d, 1H), 6.41(d, 1H), 7.01(m, 2H), 7.14(m, 2H), 8.62(s, 1H).13C-
NMR (75 MHz, CDCl3) δ: 13.19, 17.71, 27.82, 108.26, 120.66, 120.82, 121.66,
127.78, 139.92, 143.43, 152.41, 162.46, 167.63, 173.89.LC-MS(ESI, pos, ion)
m/z: 329[M+1]。
Embodiment 5：N- (3- methyl-1s, 2,4- thiadiazolyl groups -5) -4- (2,3 dimethyl phenoxy) -1H- pyrrole radicals -2-
The synthesis of formamide
The bromo- N- of 4- (3- methyl-1s, 2,4- thiadiazolyl groups -5) -1H- pyrroles -2- formamides (10 mmol) are dissolved in 30 ml
In toluene, copper sulfide (1 mmol) and cesium carbonate (12 mmol) are added thereto, stirs half an hour, is added thereto to ethyl
Phenol (12 mmol), system are reacted 10 hours after being heated to 100 DEG C.Then it is cooled to room temperature, is filtered, solvent evaporated, quick column
Chromatographic isolation can obtain 2.7 g yellow N- (3- methyl-1s, 2,4- thiadiazolyl groups -5) -4- (2,3 dimethyl phenoxy) -1H- pyrroles
Cough up base -2- formamide solids, yield 82%.1H-NMR (400 MHz, CDCl3) δ: 2.08(s, 3H), 2.18(s, 3H),
2.29(s, 3H), 6.08(d, 1H), 6.35(d, 1H), 6.79-6.89(m, 3H), 8.68(s, 1H). 13C-NMR
(75 MHz, CDCl3) δ: 13.38, 17.71, 19.79, 108.26, 117.32, 119.41, 121.66,
125.25, 125.31, 127.98, 137.11, 143.35, 154.08, 162.46, 167.63, 173.89.LC-MS
(ESI, pos, ion) m/z: 329[M+1]。
Test example 1：People and rat fat amide hydrolysis enzyme inhibition activity
The compounds of this invention is to people and rat fat hydroamidase（FAAH）Inhibitory activity, test method are same
CN103958473B, unless otherwise stated, all reagents are purchased from Sigma.It is summarized as follows：
Material and reagent：
People for analysis and rat fat hydroamidase（FAAH）Gene is by Patricelli etc.
（Biochemistry.1998,37（43）, 15177-87）Description.The fatty amide hydrolase that membrane-spanning domain is deleted（FAAH）Gene
It is cloned into pET15b（Novagen, #69661）（People FAAH）/pET28a（Novagen, #69864-3）（Rat FAAH genes）Matter
In grain and in Escherichia coli（Ecoli）It is expressed in BL21DE3.PGR07 plasmids（Takara Bio Inc, Japan）In companion's egg
White groEL-groES and fatty amide hydrolase（FAAH）Coexpression, so as to improve expression in escherichia coli protein it is molten
Xie Du.Such as Mileni（Proc NatlAcad Sci USA.2008,105（35）, 12820-4）In it is recorded, to express simultaneously
Enrichment protein.In short, using arabinose at room temperature（2mM）With isopropyl ss-D-1- thiogalactosides（IPTG）（1mM）
Induce LB culture mediums（Luria Broth）（2L）In bacterial cultures 20h.Culture is centrifuged into 10min at 1200 × g,
And by cell mass（cell pellet）It is resuspended in 100mL NaPi containing 20mM（pH7.4）, 100mM NaCl, nuclease（500u）,
Aprotinin（1μg/mL）And leupeptin（1μg/mL）Buffer solution in.Pass through sonic method（Amp 20%, pulse 15s × 15, ice
On）Lytic cell, and remove cell fragment by centrifuging 20min under 5000 × g.Suspension through exceed the speed limit under 100,000 × g from
Heart 1h enrichments, and cell mass is resuspended in 16mL NaPi containing 20mM（pH7.8）, 500mM NaCl, 1% triton x-100 it is slow
In fliud flushing.The cell extract of suspension carries out ultracentrifugation 1h under 100,000 × g, and by the suspension of enrichment for external
Analysis.All proteins extraction step carries out on ice or at 4 DEG C.
Analyzed in vitro：
The bioactivity of compound is evaluated using fluorescence-based analysis, to quantitative arachidonic base 7- amino, 4 first
Butylcoumariii amide（AAMCA）, fatty amide hydrolase（FAAH）Fluorogenic substrate hydrolysis（Anal Biochem.2005,
343(1)：143-51）.In 96 hole black polystyrene plates（Greiner Bio-one, Germany）In with 200 μ L volumes carry out
Analysis.Each reaction is by containing 50mM HEPES, 1mM EDTA and 0.1%BSA（PH7.4）Analysis buffer in people's fatty acid amide
Hydrolase（FAAH）Albumen and 10 μM of AAMCA are constituted.With the inhibitor of 2 μ L various concentrations in DMSO（The final concentration of DMSO
1%）Oscillation while incubation reaction 1min and in 50min monitor kinetics model in fluorescence increase.In excitation wavelength
Under 355nm and under 460nm transmittings, Flexstation III microplate reader is used（Molecular Devices, Sunnyvale,
CA）Measure the increase of fluorescence.The reaction rate of function used as inhibitor concentration measures the IC of inhibitor50.It uses
Graph PadPrism（Graph Pad Software Inc., San Diego, CA）Analyze data.Rat is utilized as described above
Fatty amide hydrolase（FAAH）Albumen and 10 μM of AAMCA substrates evaluate compound to rat fat hydroamidase（FAAH）
Activity.
, 1 the compounds of this invention of table is to people and rat FAAH inhibitory activity.
| hFAAH IC50（nM） | rFAAH IC50（nM） | |
| Embodiment 1 | 28 | 110 |
| Embodiment 2 | 6 | 127 |
| Embodiment 3 | 2 | 73 |
| Embodiment 4 | 17 | 82 |
| Embodiment 5 | 22 | 86 |
| OL-135 | 10 | 79 |
Inhibit to live well the result shows that the compound by test has people and rat fat hydroamidase
Property, IC50Value is within the scope of 2nM to 127nM, the IC of embodiment 350Value is 2nM.Positive control OL-135 is to people and rat fat
The inhibitory activity IC of fat hydroamidase50Value is respectively 10nM and 79nM.Illustrate that the compound of the present invention can be used as fatty acyl
Follow-up research and development of the amine hydrolase inhibitor for the preparation of related drugs.
Claims (6)
1. a kind of inhibitors of fatty amide hydrolase, structural formula are
Wherein or X is N, R1、R2、R3All it is H；Or X is CH, R1、R3For H, R2For F；Or X is CH, R1、R2All it is H, R3For
CH2CH3；Or X is CH, R1、R2For CH3, R3For H.
2. the preparation method of inhibitors of fatty amide hydrolase as described in claim 1, it is characterized in that：Synthetic route is as follows:
。
3. it is dynamic that inhibitors of fatty amide hydrolase as described in claim 1 is used to prepare treatment, prevention or auxiliary treatment lactation
Application in object and people in adjusting fatty amide hydrolase relevant disease drug.
4. application of the inhibitors of fatty amide hydrolase as described in claim 1 in the drug for preparing treatment pain.
5. a kind of composition, which is characterized in that including inhibitors of fatty amide hydrolase described in claim 1 and pharmaceutically may be used
The auxiliary material of receiving.
6. composition as claimed in claim 5, which is characterized in that inhibitors of fatty amide hydrolase described in claim 1
As sole active agent.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711010260.7A CN107602550B (en) | 2017-10-25 | 2017-10-25 | A kind of inhibitors of fatty amide hydrolase and preparation method thereof |
| CN201810457983.XA CN108409727A (en) | 2017-10-25 | 2017-10-25 | A kind of inhibitors of fatty amide hydrolase and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711010260.7A CN107602550B (en) | 2017-10-25 | 2017-10-25 | A kind of inhibitors of fatty amide hydrolase and preparation method thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810457983.XA Division CN108409727A (en) | 2017-10-25 | 2017-10-25 | A kind of inhibitors of fatty amide hydrolase and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107602550A CN107602550A (en) | 2018-01-19 |
| CN107602550B true CN107602550B (en) | 2018-10-23 |
Family
ID=61080386
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711010260.7A Active CN107602550B (en) | 2017-10-25 | 2017-10-25 | A kind of inhibitors of fatty amide hydrolase and preparation method thereof |
| CN201810457983.XA Withdrawn CN108409727A (en) | 2017-10-25 | 2017-10-25 | A kind of inhibitors of fatty amide hydrolase and preparation method thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810457983.XA Withdrawn CN108409727A (en) | 2017-10-25 | 2017-10-25 | A kind of inhibitors of fatty amide hydrolase and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN107602550B (en) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008023720A1 (en) * | 2006-08-23 | 2008-02-28 | Astellas Pharma Inc. | Urea compound or salt thereof |
| JO3598B1 (en) * | 2006-10-10 | 2020-07-05 | Infinity Discovery Inc | Boronic acids and esters as inhibitors of fatty acid amide hydrolase |
| TWI434842B (en) * | 2008-07-14 | 2014-04-21 | Astellas Pharma Inc | Azole compounds |
| CA2780905A1 (en) * | 2009-12-11 | 2011-06-16 | E.I. Du Pont De Nemours And Company | Azocyclic inhibitors of fatty acid amide hydrolase |
| WO2015200682A1 (en) * | 2014-06-25 | 2015-12-30 | Vanderbilt University | Substituted 4-alkoxypicolinamide analogs ds mglur5 negative allosteric modulators |
-
2017
- 2017-10-25 CN CN201711010260.7A patent/CN107602550B/en active Active
- 2017-10-25 CN CN201810457983.XA patent/CN108409727A/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CN107602550A (en) | 2018-01-19 |
| CN108409727A (en) | 2018-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10059657B2 (en) | Class-and isoform-specific HDAC inhibitors and uses thereof | |
| Brown et al. | The structure–activity relationship of urea derivatives as anti-tuberculosis agents | |
| Yang et al. | Discovery of 2-((4, 6-dimethylpyrimidin-2-yl) thio)-N-phenylacetamide derivatives as new potent and selective human sirtuin 2 inhibitors | |
| Rahim et al. | Synthesis of new arylhydrazide bearing Schiff bases/thiazolidinone: α-Amylase, urease activities and their molecular docking studies | |
| Hassan et al. | Synthesis of 3-benzyl-2-substituted quinoxalines as novel monoamine oxidase A inhibitors | |
| Suzuki et al. | Novel histone deacetylase inhibitors: design, synthesis, enzyme inhibition, and binding mode study of SAHA-based non-hydroxamates | |
| Li et al. | Expression and functional characterization of recombinant human HDAC1 and HDAC3 | |
| Zhou et al. | Development of highly potent phosphodiesterase 4 inhibitors with anti-neuroinflammation potential: design, synthesis, and structure-activity relationship study of catecholamides bearing aromatic rings | |
| Kaya et al. | Synthesis of some novel 2-substituted benzothiazole derivatives containing benzylamine moiety as monoamine oxidase inhibitory agents | |
| Roshdy et al. | Selective SIRT2 inhibitors as promising anticancer therapeutics: An update from 2016 to 2020 | |
| CN116897153A (en) | Triazole derivative and preparation method and application thereof | |
| Liu et al. | 1, 4-Naphthoquinones as inhibitors of Itch, a HECT domain-E3 ligase, and tumor growth suppressors in multiple myeloma | |
| Shah et al. | Newer human inosine 5′-monophosphate dehydrogenase 2 (h IMPDH2) inhibitors as potential anticancer agents | |
| Varghese et al. | Alkyl-substituted polyaminohydroxamic acids: a novel class of targeted histone deacetylase inhibitors | |
| Routholla et al. | Design, synthesis and binding mode of interaction of novel small molecule o-hydroxy benzamides as HDAC3-selective inhibitors with promising antitumor effects in 4T1-Luc breast cancer xenograft model | |
| Jin et al. | Design, synthesis and preliminary biological evaluation of indoline-2, 3-dione derivatives as novel HDAC inhibitors | |
| Andrianov et al. | Novel amide derivatives as inhibitors of histone deacetylase: Design, synthesis and SAR | |
| Chepanova et al. | Effective inhibitors of tyrosyl-DNA phosphodiesterase 1 based on monoterpenoids as potential agents for antitumor therapy | |
| CN107602550B (en) | A kind of inhibitors of fatty amide hydrolase and preparation method thereof | |
| Xin et al. | Design and synthesis of α-phenoxy-N-sulfonylphenyl acetamides as Trypanosoma brucei Leucyl-tRNA synthetase inhibitors | |
| Peng et al. | Degrasyn-like symmetrical compounds: possible therapeutic agents for multiple myeloma (MM-I) | |
| Nadaroglu et al. | Investigation of the inhibitory effects of isoindoline-1, 3-dion derivatives on hCA-I and hCA-II enzyme activities | |
| Ji et al. | Conformationally restricted dipeptide amides as potent and selective neuronal nitric oxide synthase inhibitors | |
| Li et al. | Optical evodiamine derivatives: Asymmetric synthesis and antitumor activity | |
| Li et al. | Design and synthesis of N-(3-sulfamoylphenyl) amides as Trypanosoma brucei leucyl-tRNA synthetase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20180903 Address after: 322300 B25, small and medium enterprises Incubation Park, new town, Panan, Jinhua, Zhejiang Applicant after: Panan County Chen Xi arts and Crafts Co., Ltd. Address before: 262600 Wolong Town, Linqu County, Weifang, Shandong Applicant before: Ju Defeng |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20191206 Address after: Room a401-6, Jinshiji Fortune Building, Huzhou Economic and Technological Development Zone, Huzhou City, Zhejiang Province Patentee after: Huzhou Shizi Hede Health Management Co., Ltd Address before: 322300 B25, small and medium enterprises Incubation Park, new town, Panan, Jinhua, Zhejiang Patentee before: Panan County Chen Xi arts and Crafts Co., Ltd. |